Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)

<p>Study Schema</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Arathi Mohan (15561346) (author)
Altres autors:	Kent A. Griffith (15561349) (author), Fulei Wuchu (15561352) (author), David B. Zhen (15561355) (author), Chandan Kumar-Sinha (15130650) (author), Oxana Crysler (15561358) (author), David Hsiehchen (15561361) (author), Thomas Enzler (15561364) (author), Dominique Dippman (15561367) (author), Valerie Gunchick (15560621) (author), Abhinav Achreja (15561370) (author), Olamide Animasahun (15561373) (author), Srinadh Choppara (15561376) (author), Minal Nenwani (15561379) (author), Arul M. Chinnaiyan (15561382) (author), Deepak Nagrath (15561385) (author), Mark M. Zalupski (15561388) (author), Vaibhav Sahai (15560624) (author)
Publicat:	2025
Matèries:	Cancer Therapeutic Research and Development Clinical Research and Trials Clinical Trial Results Phase I clinical trials Gastrointestinal Cancers Liver cancer Translational Research
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
per: Arathi Mohan (15561346)
Publicat: (2025)

Supplementary Table 2 from Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer
per: Patrick M. Grierson (17535179)
Publicat: (2025)

Supplementary Figure 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 2 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 3 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Figure 4 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Supplementary Table 1 from A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
per: Tom Wei-Wu Chen (15053003)
Publicat: (2025)

Figure 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
per: Andre L. De Souza (22819921)
Publicat: (2025)

Figure 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
per: Andre L. De Souza (22819921)
Publicat: (2025)

Table 1 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
per: Andre L. De Souza (22819921)
Publicat: (2025)

Table 2 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
per: Andre L. De Souza (22819921)
Publicat: (2025)

Table 3 from BrUOG360: A Phase Ib/II Study of Copanlisib in Combination with Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
per: Andre L. De Souza (22819921)
Publicat: (2025)

Table 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
per: Jinhui Xue (22548163)
Publicat: (2025)

Table 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
per: Jinhui Xue (22548163)
Publicat: (2025)

Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
per: Jinhui Xue (22548163)
Publicat: (2025)

Figure 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
per: Jinhui Xue (22548163)
Publicat: (2025)

Figure 3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
per: Jinhui Xue (22548163)
Publicat: (2025)

Figure 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
per: Luis Manso (15027360)
Publicat: (2025)

Figure 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
per: Luis Manso (15027360)
Publicat: (2025)

Figure 3 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
per: Luis Manso (15027360)
Publicat: (2025)

Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
per: Luis Manso (15027360)
Publicat: (2025)

Table 2 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
per: Luis Manso (15027360)
Publicat: (2025)

Figure 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
per: Mamta Parikh (15062872)
Publicat: (2025)

Figure 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
per: Mamta Parikh (15062872)
Publicat: (2025)

Table 1 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
per: Mamta Parikh (15062872)
Publicat: (2025)

Table 2 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
per: Mamta Parikh (15062872)
Publicat: (2025)

Table 3 from The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
per: Mamta Parikh (15062872)
Publicat: (2025)

Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
per: Zev A. Wainberg (15047031)
Publicat: (2025)

Supplementary Figure S1 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Figure S2 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Figure S3 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Figure S4 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Figure S5 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Figure S6 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Table S1 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)

Supplementary Table S10 from Measles Oncolytic Virus as an Immunotherapy for Recurrent/Refractory Pediatric Medulloblastoma and Atypical Teratoid/Rhabdoid Tumor: Results from PNOC005
per: Bohyeon Yu (16721711)
Publicat: (2025)